Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages.
Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 30, 21 | -0.16 Decreased by -68.22% | - |
| Mar 31, 21 | -0.16 Decreased by -69.59% | - |
| Dec 31, 20 | -0.13 | - |
| Sep 30, 20 | -0.12 | - |
| Jun 30, 20 | -0.10 | - |
| Mar 31, 20 | -0.09 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Mar 31, 23 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Jun 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Mar 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Dec 31, 21 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 21 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |